Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001090550 | SCV001246157 | uncertain significance | not provided | 2019-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001228310 | SCV001400705 | likely benign | Hereditary spastic paraplegia 7 | 2023-03-27 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001847152 | SCV002105896 | uncertain significance | Hereditary spastic paraplegia | 2019-12-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001090550 | SCV003936212 | uncertain significance | not provided | 2022-12-28 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004031224 | SCV004956562 | uncertain significance | Inborn genetic diseases | 2024-03-07 | criteria provided, single submitter | clinical testing | The c.638G>A (p.R213Q) alteration is located in exon 5 (coding exon 5) of the SPG7 gene. This alteration results from a G to A substitution at nucleotide position 638, causing the arginine (R) at amino acid position 213 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |